ClinicalTrials.gg
CompletedNCT04102098IMbrave050Updated Jun 18, 2026Results posted

A Study of Atezolizumab Plus Bevacizumab Versus Active Surveillance as Adjuvant Therapy in Patients With Hepatocellular Carcinoma at High Risk of Recurrence After Surgical Resection or Ablation

A Phase 3 interventional study of Atezolizumab and Bevacizumab in Carcinoma, Hepatocellular, sponsored by Hoffmann-La Roche. Completed at 134 sites in 26 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-18.

Sponsored by Hoffmann-La Roche · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
668
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 41 studies testing atezolizumab in Carcinoma, Hepatocellular — 17 open to participants now, 29 under way, 7 of them phase 3. atezolizumab · Carcinoma, Hepatocellular.

Enrollment
3rd of 41
668 · median 40
Started
2019
with 1 other
Phase 3
11 of 41
2 open now
Registered
4th of 41
by date
Lead sponsor
6 of 41
Hoffmann-La Roche

Among the 41 studies testing atezolizumab in Carcinoma, Hepatocellular, this one is the 3rd largest by enrollment, is one of 2 that started in 2019, is one of 11 in phase 3, and was the 4th registered.

Carcinoma, Hepatocellular

3,651 studies on the registry are indexed under Carcinoma, Hepatocellular; 1,063 are open to participants now.

Browse Carcinoma, Hepatocellular studies →

Open to participants now

17 of the 41 studies testing atezolizumab in Carcinoma, Hepatocellular are open now, in 11 countries. Recruiting first, the newest first:

12 more — sign in →

By country, each count listing its studies:

All 17 open studies →

About atezolizumab

atezolizumab: first FDA approval 2016 (TECENTRIQ), first EMA approval 2017. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 739 Carcinoma, Hepatocellular studies recruiting now, 383 (52%) set no upper age limit and 249 (34%) stop at 75 or younger; 31 take children under 18; 31 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 41 studies testing atezolizumab in Carcinoma, Hepatocellular, or all of them as a file.
02

Study summary

This study will evaluate the efficacy and safety of adjuvant therapy with atezolizumab plus bevacizumab compared with active surveillance in participants with completely resected or ablated hepatocellular carcinoma (HCC) who are at high risk for disease recurrence.

03

Conditions studied

  • Carcinoma, Hepatocellular
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants with a first diagnosis of HCC who have undergone either a curative resection or ablation (radiofrequency ablation [RFA] or microwave ablation [MVA] only) within 4-12 weeks prior to randomization
  • Documented diagnosis of HCC that has been completely resected or ablated (RFA or MVA only)
  • Absence of major macrovascular invasion (except Vp1/Vp2) and extrahepatic spread
  • Absence of extrahepatic spread as confirmed by CT or MRI scan of the chest, abdomen, pelvis, and head prior to and following curative procedure
  • Full recovery from surgical resection or ablation within 4 weeks prior to randomization
  • High risk for HCC recurrence after resection or ablation
  • For patients who received post-operative transarterial chemoembolization: full recovery from the procedure within 4 weeks prior to randomization
  • For patients with resected HCC, availability of a representative baseline tumor tissue sample
  • Performance Status of 0 or 1
  • Class A status
  • Adequate hematologic and end-organ function
  • For women of : agreement to remain abstinent (refrain from heterosexual intercourse) or use methods
  • For men: agreement to remain abstinent (refrain from heterosexual intercourse) or use a condom, and agreement to refrain from donating sperm

Exclusion criteria

Exclusion Criteria:

  • Known fibrolamellar HCC, sarcomatoid HCC, or mixed cholangiocarcinoma and HCC
  • Evidence of residual, recurrent, or disease at randomization
  • ascites
  • History of hepatic encephalopathy
  • Prior bleeding event due to untreated or incompletely treated esophageal and/or gastric varices within 6 months prior to randomization
  • Have received more than 1 cycle of adjuvant TACE following surgical resection
  • Active or history of disease or immune deficiency
  • History of idiopathic pulmonary fibrosis, organizing pneumonia, drug-induced pneumonitis, or idiopathic pneumonitis, or evidence of active pneumonitis on screening chest CT scan
  • Significant cardiovascular disease within 3 months prior to Day 1 of Cycle 1, unstable arrhythmia, or unstable angina
  • History of other than HCC within 5 years prior to screening, with the exception of malignancies with a negligible risk of metastasis or death
  • Active tuberculosis
  • Any other disease, metabolic dysfunction, physical examination finding, or clinical laboratory finding that contraindicates the use of an drug, may affect the interpretation of the results, or may render the patient at high risk from treatment complications
  • Pregnant or breastfeeding, or intending to become pregnant during the study or within 5 months after the final dose of atezolizumab or within 6 months after the final dose of bevacizumab. Women of must have a negative serum pregnancy test result within 14 days prior to Day 1 of Cycle 1.
  • Co-infection with and
  • Co-infection with HBV and hepatitis D viral infection
  • Clinical significant uncontrolled or symptomatic hypercalcemia
  • Any treatment for HCC prior to resection or ablation, including systemic therapy and locoregional therapy such as TACE
  • Treatment with systemic immunostimulatory or agents
  • Inadequately controlled arterial hypertension
  • History of hypertensive crisis or hypertensive encephalopathy
  • Significant vascular disease
  • Evidence of bleeding diathesis or significant coagulopathy
  • Current or recent use of aspirin or full-dose oral or parenteral anticoagulants
  • Core within 3 days of Day 1 of Cycle 1
  • History of GI fistula, GI perforation, or intra-abdominal abscess
  • Serious non-healing or dehiscing wound
  • Major surgical procedure within four weeks
  • Chronic daily treatment with a non-steroidal anti-inflammatory drug
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
668 participants (actual)

Study arms

  • Experimental
    Arm A (atezolizumab plus bevacizumab)

    Participants will receive Atezolizumab + Bevacizumab until disease recurrence or unacceptable toxicity.

    Drug: Atezolizumab · Drug: Bevacizumab

  • No intervention
    Arm B (active surveillance)

    Active surveillance of participants.

Interventions

  • Atezolizumab 1200 mg will be administered by IV infusion on Day 1 of each 21-day cycle.

    Also known as: Tecentriq

  • Bevacizumab will be administered by IV infusion at a dose of 15 mg/kg on Day 1 of each 21-day cycle.

    Also known as: Avastin

06

What researchers measure

Primary outcomes

  1. Recurrence-Free Survival (RFS), as Determined by IRF

    RFS is defined as the time from randomization to the first documented occurrence of intrahepatic or extrahepatic HCC as determined by an IRF, or death from any cause (whichever occurs first).

    Time frame: Baseline up to approximately 33 months

Secondary outcomes

  1. Overall Survival (OS)

    OS is defined as the time from randomization to death from any cause.

    Time frame: Baseline up to approximately 91 months

  2. RFS as Determined by the Investigator

    RFS is defined as the time from randomization to the first documented occurrence of intrahepatic or extrahepatic HCC as determined by an investigator, or death from any cause (whichever occurs first).

    Time frame: Baseline up to approximately 91 months

  3. Time to Recurrence (TTR)

    TTR defined as the time from randomization to first documented occurrence of intrahepatic or extrahepatic HCC, as determined by the investigator and by an IRF.

    Time frame: Baseline up to approximately 91 months

  4. RFS Rate at 24 and 36 Months, as Assessed by the IRF

    Time frame: Randomization up to 24 months and up to 36 months

  5. RFS Rate at 24 and 36 Months, as Assessed by the Investigator

    Time frame: Randomization up to 24 months and up to 36 months

  6. OS Rate at 24 and 36 Months

    OS rate defined as the proportion of patients who have not experienced death from any cause at 24 and 36 months after randomization.

    Time frame: Baseline to 24 and 36 months

  7. Time to Extrahepatic Spread (EHS) or Macrovascular Invasion

    Time to EHS or macrovascular invasion after randomization, defined as the time from randomization to the first appearance of EHS or macrovascular invasion, as determined by the investigator.

    Time frame: Baseline up to approximately 91 months

  8. RFS in Pd-L1-High Subgroup

    RFS after randomization as determined by the investigator and by an IRF, among patients in the PD-L1-high subgroup.

    Time frame: Baseline up to approximately 91 months

  9. Percentage of Participants With Adverse Events

    Time frame: Baseline up to approximately 91 months

  10. Serum Concentration of Atezolizumab

    Serum concentration of atezolizumab.

    Time frame: Prior to any drug administration on Day 1 of Cycles 1, 2, 3, 4, 8, 12, and 16, and 30 minutes after end of atezolizumab infusion on Day 1 of Cycle 1 (each cycle is 21 days)

  11. Number of Participants With Anti-Drug Antibodies (ADAs) to Atezolizumab

    Number of participants with anti-drug antibodies to atezolizumab.

    Time frame: Prior to any drug administration up to approximately 33 month

07

Results

Posted Nov 18, 2023

Participant flow

This study was conducted at 134 centers in 26 countries/regions.

Main Study Period
Participant flow — Main Study Period
MilestoneActive SurveillanceAtezolizumab + Bevacizumab
Started334334
Completed00
Not completed334334
Withdrew: Ongoing in study302291
Withdrew: Death2027
Withdrew: Lost to follow-up11
Withdrew: Physician decision01
Withdrew: Withdrawal by subject1114
Crossover: AS Who Crossed Over
Participant flow — Crossover: AS Who Crossed Over
MilestoneActive SurveillanceAtezolizumab + Bevacizumab
Started810
Completed00
Not completed810
Withdrew: Withdrawal by subject10
Withdrew: Death110
Withdrew: Ongoing in study690

Outcome measures

PrimaryRecurrence-Free Survival (RFS), as Determined by IRF

RFS is defined as the time from randomization to the first documented occurrence of intrahepatic or extrahepatic HCC as determined by an IRF, or death from any cause (whichever occurs first).

Time frame:
Baseline up to approximately 33 months
Reported as:
Median · Months
Recurrence-Free Survival (RFS), as Determined by IRF
MonthsArm B (Active Surveillance)Arm A (Atezolizumab Plus Bevacizumab)
Recurrence-Free Survival (RFS), as Determined by IRFNA (21.4 to NA)NA (22.1 to NA)
Statistical analysis
  • Arm B (Active Surveillance) vs Arm A (Atezolizumab Plus Bevacizumab) · Log Rank · p = 0.0120 · Hazard ratio (hr): 0.72 · 95% CI 0.56 to 0.93
SecondaryOverall Survival (OS)

OS is defined as the time from randomization to death from any cause.

Time frame:
Baseline up to approximately 91 months

Results for this outcome have not been posted.

SecondaryRFS as Determined by the Investigator

RFS is defined as the time from randomization to the first documented occurrence of intrahepatic or extrahepatic HCC as determined by an investigator, or death from any cause (whichever occurs first).

Time frame:
Baseline up to approximately 91 months

Results for this outcome have not been posted.

SecondaryTime to Recurrence (TTR)

TTR defined as the time from randomization to first documented occurrence of intrahepatic or extrahepatic HCC, as determined by the investigator and by an IRF.

Time frame:
Baseline up to approximately 91 months

Results for this outcome have not been posted.

SecondaryRFS Rate at 24 and 36 Months, as Assessed by the IRF
Time frame:
Randomization up to 24 months and up to 36 months

Results for this outcome have not been posted.

SecondaryRFS Rate at 24 and 36 Months, as Assessed by the Investigator
Time frame:
Randomization up to 24 months and up to 36 months

Results for this outcome have not been posted.

SecondaryOS Rate at 24 and 36 Months

OS rate defined as the proportion of patients who have not experienced death from any cause at 24 and 36 months after randomization.

Time frame:
Baseline to 24 and 36 months

Results for this outcome have not been posted.

SecondaryTime to Extrahepatic Spread (EHS) or Macrovascular Invasion

Time to EHS or macrovascular invasion after randomization, defined as the time from randomization to the first appearance of EHS or macrovascular invasion, as determined by the investigator.

Time frame:
Baseline up to approximately 91 months

Results for this outcome have not been posted.

SecondaryRFS in Pd-L1-High Subgroup

RFS after randomization as determined by the investigator and by an IRF, among patients in the PD-L1-high subgroup.

Time frame:
Baseline up to approximately 91 months

Results for this outcome have not been posted.

SecondaryPercentage of Participants With Adverse Events
Time frame:
Baseline up to approximately 91 months

Results for this outcome have not been posted.

SecondarySerum Concentration of Atezolizumab

Serum concentration of atezolizumab.

Time frame:
Prior to any drug administration on Day 1 of Cycles 1, 2, 3, 4, 8, 12, and 16, and 30 minutes after end of atezolizumab infusion on Day 1 of Cycle 1 (each cycle is 21 days)
Reported as:
Mean · μg/ mL
Serum Concentration of Atezolizumab
μg/ mLArm A (Atezolizumab Plus Bevacizumab)
Cycle 1 Day 1NA ± NA
Cycle 1 Day 1, 30 Min After End of Atezo440 ± 132
Cycle 2 Day 188.7 ± 30.4
Cycle 3 Day 1137 ± 53.0
Cycle 4 Day 1159 ± 58.5
Cycle 8 Day 1196 ± 86.2
Cycle 12 Day 1202 ± 90.1
Cycle 16 Day 1204 ± 89.2
SecondaryNumber of Participants With Anti-Drug Antibodies (ADAs) to Atezolizumab

Number of participants with anti-drug antibodies to atezolizumab.

Time frame:
Prior to any drug administration up to approximately 33 month
Reported as:
Number · Participants
Number of Participants With Anti-Drug Antibodies (ADAs) to Atezolizumab
ParticipantsArm A (Atezolizumab Plus Bevacizumab)
Baseline evaluable participants8
Post-baseline evaluable participants75

Adverse events

Collected over From the first study drug administration to the data cutoff date: 21 October 2022 (up to approximately 33 months).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Active Surveillance20/334 (6%)34/330 (10.3%)111/330 (33.6%)
Atezolizumab+Bevacizumab27/334 (8.1%)80/332 (24.1%)296/332 (89.2%)
Crossover: Atezolizumab+Bevacizumab11/81 (13.6%)10/81 (12.3%)63/81 (77.8%)
Most frequent serious events
Showing 10 of 132
Most frequent serious events
EventActive SurveillanceAtezolizumab+BevacizumabCrossover: Atezolizumab+Bevacizumab
PyrexiaGeneral disorders0/3301/3323/81
Oesophageal varices haemorrhageGastrointestinal disorders2/3305/3320/81
Febrile neutropeniaBlood and lymphatic system disorders0/3300/3321/81
Thrombotic microangiopathyBlood and lymphatic system disorders0/3300/3321/81
Cardiac failureCardiac disorders0/3301/3321/81
Cardiac failure congestiveCardiac disorders0/3300/3321/81
HaemorrhoidsGastrointestinal disorders0/3300/3321/81
HerniaGeneral disorders0/3300/3321/81
Anaphylactic reactionImmune system disorders1/3300/3321/81
Upper respiratory tract infectionInfections and infestations0/3301/3321/81
Most frequent other events
Showing 10 of 28
Most frequent other events
EventActive SurveillanceAtezolizumab+BevacizumabCrossover: Atezolizumab+Bevacizumab
ProteinuriaRenal and urinary disorders12/330153/33225/81
HypertensionVascular disorders10/330126/33225/81
Platelet count decreasedInvestigations22/33066/33217/81
Aspartate aminotransferase increasedInvestigations18/33051/33213/81
Alanine aminotransferase increasedInvestigations18/33046/33212/81
HypothyroidismEndocrine disorders1/33047/3329/81
ArthralgiaMusculoskeletal and connective tissue disorders8/33040/3328/81
PruritusSkin and subcutaneous tissue disorders3/33040/3326/81
RashSkin and subcutaneous tissue disorders1/33040/3329/81
PyrexiaGeneral disorders7/33033/3326/81

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Arm B (Active Surveillance)Arm A (Atezolizumab Plus Bevacizumab)Total
Mean58.9 ± 12.559.0 ± 12.159.0 ± 12.3
Sex: Female, Male
Sex: Female, Male(Participants)Arm B (Active Surveillance)Arm A (Atezolizumab Plus Bevacizumab)Total
Female5657113
Male278277555
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Arm B (Active Surveillance)Arm A (Atezolizumab Plus Bevacizumab)Total
American Indian or Alaska Native134
Asian269276545
Native Hawaiian or Other Pacific Islander101
Black or African American123
White413576
More than one race022
Unknown or Not Reported211637
08

Study locations

134 sites
  • Kaiser Permanente Los Angeles
    Los Angeles, California 90027, United States
  • Mercy Medical Center
    Baltimore, Maryland 21202, United States
  • Henry Ford Health System
    Detroit, Michigan 48202, United States
  • Columbia University Medical Center
    New York, New York 10032, United States
  • Thomas Jefferson University
    Philadelphia, Pennsylvania 19107, United States
  • The University of Texas Southwestern Medical Center at Dallas
    Dallas, Texas 75390, United States
  • MD Anderson Cancer Center
    Houston, Texas 77030, United States
  • Swedish Cancer Inst.
    Seattle, Washington 98104, United States
  • St Vincent's Hospital Sydney
    Darlinghurst, New South Wales 2010, Australia
  • Lkh-Univ. Klinikum Graz
    Graz, 8036, Austria
  • Klinikum Klagenfurt am Wörtersee
    Klagenfurt, 9020, Austria
  • Medizinische Universität Wien
    Vienna, 1090, Austria
  • Imeldaziekenhuis
    Bonheiden, 2820, Belgium
  • AZ Delta (Campus Rumbeke)
    Roeselare, 8800, Belgium
  • Hospital Sao Rafael - HSR
    Salvador, Estado de Bahia 41253-190, Brazil
  • Sociedade beneficente de senhoras Hospital Sirio Libanes
    Brasília, Federal District 70200-730, Brazil
  • Hospital do Cancer UOPECCAN
    Cascavel, Paraná 85806-300, Brazil
  • Hospital Alemao Oswaldo Cruz
    São Paulo, São Paulo 01323-020, Brazil
  • Gordon & Leslie Diamond Health Care Centre
    Vancouver, British Columbia V5Z 1M9, Canada
  • McGill University Health Centre - Glen Site
    Montreal, Quebec H4A 3J1, Canada
  • Anhui Provincial Hospital
    Anhui, 230001, China
  • Beijing Cancer Hospital
    Beijing, 100142, China
  • Peking Union Medical College Hospital
    Beijing, 100730, China
  • Affiliated Hospital of Bengbu Medical College
    Bengbu, 233004, China
  • The First Hospital of Jilin University
    Changchun, 130021, China
  • West China Hospital, Sichuan University
    Chengdu, 610041, China
  • Daping Hospital of Third Military Medical University
    Chongqing, 400042, China
  • The Second Affiliated Hospital of Dalian Medical University
    Dalian, 116027, China
  • Fujian Cancer Hospital
    Fuzhou, 350014, China
  • Mengchao Hepatobiliary Hospital Of Fujian Medical University
    Fuzhou, 350025, China
  • Cancer Center of Guangzhou Medical University
    Guangzhou, 510000, China
  • Sun Yet-sen University Cancer Center
    Guangzhou, 510060, China
  • Zhujiang Hospital, Southern Medical University
    Guangzhou, 510280, China
  • Nanfang Hospital, Southern Medical University
    Guangzhou, 510515, China
  • Zhejiang Cancer Hospital
    Hangzhou, 310022, China
  • Harbin Medical University Cancer Hospital
    Harbin, 150081, China
  • Anhui Province Cancer Hospital
    Hefei, 12345, China
  • The Second Affiliated Hospital of Anhui Medical University
    Hefei, 230601, China
  • Shandong Cancer Hospital
    Jinan, 250117, China
  • The 81st Hospital of P.L.A.
    Nanjing, 210002, China
  • Zhongda Hospital Affiliated to Southeast University
    Nanjing, 210009, China
  • Nanjing Drum Tower Hospital, the Affiliated Hospital of Nanjing University Medical School
    Nanjing, 210029, China
  • Guangxi Cancer Hospital of Guangxi Medical University
    Nanning, 530021, China
  • The First Affiliate Hospital of Guangxi Medical University
    Nanning, 530021, China
  • Fudan University Shanghai Cancer Center
    Shanghai, 200032, China
  • Huashan Hospital Affiliated to Fudan University
    Shanghai, 200040, China
  • Renji Hospital Affiliated to Shanghai Jiao Tong University School of Medicine
    Shanghai, 200127, China
  • Zhongshan Hospital Fudan Unvierstiy
    Shanghai, China
  • The First Affiliated Hospital of China Medical University
    Shenyang, 110001, China
  • Shengjing Hospital of China Medical University
    Shenyang, 110004, China
  • Tianjin Cancer Hospital
    Tianjin, 300060, China
  • The Tumor Hospital of Xinjiang Medical University
    Ürümqi, 830000, China
  • Wuhan Union Hospital Tongji Medical College, Huazhong University of Science and Technology
    Wuhan, 430022, China
  • Renmin Hospital of Wuhan University
    Wuhan, 430060, China
  • Zhongnan Hospital of Wuhan University
    Wuhan, 430071, China
  • Northern Jangsu People's Hospital
    Yangzhou, China
  • Clinica CIMCA
    San José, 10103, Costa Rica
  • Fakultni nemocnice Brno
    Brno, 625 00, Czechia
  • Fakultni Thomayerova Nemocnice
    Prague, 140 59, Czechia
  • Hopital Jean Minoz
    Besançon, 25030, France
  • Hôpital Avicenne - Groupement Hospitalier Universitaire Paris Seine St Denis
    Bobigny, 93009, France
  • Hôpital Albert Michallon
    La Tronche, 38700, France
  • Fondation Hopital Saint Joseph
    Marseille, 13285, France
  • CHU Bordeaux - Hôpital Haut-Lévêque
    Pessac, 33604, France
  • Hopital Robert Debre
    Reims, 51092, France
  • Hopital de Pontchaillou
    Rennes, 35033, France
  • CHU de Toulouse - Hôpital Rangueil
    Toulouse, 31059, France
  • Hopitaux de Brabois - Gastro-Entereologie
    Vandœuvre-lès-Nancy, 54511, France
  • Universitätsklinikum Bonn, Medizinische Klinik und Poliklinik I.
    Bonn, 53127, Germany
  • Klinik Johann Wolfgang von Goethe Uni
    Frankfurt am Main, 60590, Germany
  • Klinikum der Uni Regensburg
    Regensburg, 93053, Germany
  • Universitätsklinikum Ulm
    Ulm, 89081, Germany
  • Queen Mary Hospital
    Hong Kong, Hong Kong
  • Prince of Wales Hospital
    Shatin, Hong Kong
  • Ospedale Regionale Di Parma
    Parma, Emilia-Romagna 43100, Italy
  • Ospedale Maggiore Policlinico
    Milan, Lombardy 20122, Italy
  • Asst Santi Paolo E Carlo
    Milan, Lombardy 20142, Italy
  • Azlenda Ospendaliero-Universitaria Pisana
    Pisa, Tuscany 56100, Italy
  • Chiba University Hospital
    Chiba, 260-8677, Japan
  • Ehime Prefectural Central Hospital
    Ehime, 790-0024, Japan
  • Hiroshima University Hospital
    Hiroshima, 734-8551, Japan
  • Sapporo Kosei General Hospital
    Hokkaido, 060-0033, Japan
  • Hyogo Medical University Hospital
    Hyōgo, 663-8501, Japan
  • Japanese Red Cross Society Himeji Hospital
    Hyōgo, 670-8540, Japan
  • Kanazawa University Hospital
    Ishikawa, 920-8641, Japan
  • Yokohama City University Medical Center
    Kanagawa, 232-0024, Japan
  • Kanagawa Cancer Center
    Kanagawa, 241-8515, Japan
  • Kitasato University Hospital
    Kanagawa, 252-0375, Japan
  • Kumamoto University Hospital
    Kumamoto, 860-8556, Japan
  • Osaka Red Cross Hospital
    Osaka, 543-8555, Japan
  • Kindai University Hospital
    Osaka, 589-8511, Japan
  • Tokushima University Hospital
    Tokushima, 770-8503, Japan
  • Toranomon Hospital
    Tokyo, 105-8470, Japan
  • The University of Tokyo Hospital
    Tokyo, 113-8655, Japan
  • Japanese Red Cross Musashino Hospital
    Tokyo, 180-8610, Japan
  • Filios Alta Medicina
    Monterrey, Nuevo León 64460, Mexico
  • Oaxaca Site Management Organization
    Oaxaca City, 68000, Mexico
  • Maastricht University Medical Center
    Maastricht, 6229 HX, Netherlands
  • Auckland City Hospital
    Auckland, 1023, New Zealand
  • Instituto Nacional de Enfermedades Neoplasicas
    Lima, 15038, Peru

Showing the first 100 of 134 sites across 26 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Yopp A, Chen M, Cheng AL, Kaseb A, Kudo M, Lee HC, Cha E, Hack SP, Lian Q, Spahn J, Wu C, Qin S, Chow PK. Updated data from IMbrave050: Adjuvant atezolizumab plus bevacizumab for high-risk hepatocellular carcinoma. J Hepatol. 2026 Jun;84(6):1102-1111. doi: 10.1016/j.jhep.2026.01.006. Epub 2026 Jan 22. PubMed 41580093 ↗
  • Qin S, Chen M, Cheng AL, Kaseb AO, Kudo M, Lee HC, Yopp AC, Zhou J, Wang L, Wen X, Heo J, Tak WY, Nakamura S, Numata K, Uguen T, Hsiehchen D, Cha E, Hack SP, Lian Q, Ma N, Spahn JH, Wang Y, Wu C, Chow PKH; IMbrave050 investigators. Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3 trial. Lancet. 2023 Nov 18;402(10415):1835-1847. doi: 10.1016/S0140-6736(23)01796-8. Epub 2023 Oct 20. PubMed 37871608 ↗
  • Hack SP, Spahn J, Chen M, Cheng AL, Kaseb A, Kudo M, Lee HC, Yopp A, Chow P, Qin S. IMbrave 050: a Phase III trial of atezolizumab plus bevacizumab in high-risk hepatocellular carcinoma after curative resection or ablation. Future Oncol. 2020 May;16(15):975-989. doi: 10.2217/fon-2020-0162. Epub 2020 Apr 30. PubMed 32352320 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — For eligible studies, qualified researchers may request access to individual patient level clinical data. See Roche's commitment to transparency of clinical study information here: https://go.roche.com/data_sharing

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2019 to primary completion in Oct 2022, 33 months.

Results were first posted in Nov 2023, 1 year after primary completion.

Of 53 industry-sponsored phase 3 interventional studies under Carcinoma, Hepatocellular, half reached primary completion within 53 months of starting (the median), counting those still running; a quarter within 41 and three quarters within 63. This study's 33 months is below that.

Counting every sponsor, half of 139 studies reached it within 56 months; a quarter within 43 and three quarters within 83.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 23, 2019
First posted
Sep 25, 2019
StartActual
Dec 31, 2019
Primary completionActual
Oct 21, 2022
CompletionActual
May 15, 2026
Results first posted
Nov 18, 2023
Last update
Jun 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 18, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04102098
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Sep 25, 2019
Start date
Dec 31, 2019
Primary completion
Oct 21, 2022
Completion
May 15, 2026
Results posted
Nov 18, 2023
Last update
Jun 18, 2026

Study contacts

Clinical Trials
study director · Hoffmann-La Roche

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Atezolizumab · Bevacizumab

Start the discussion